Summary
- US equity indices poised to open higher on optimistic trade comments
- S&P 500 (US500) bounces off the lower limit of the trading range
- US biotechs make big moves in the pre-market trading on major drug patent deal
Global stock markets took a hit on Friday when China announced new tariffs on US goods. United States announced retaliation after markets close. However, the US indices are set to open higher on Monday as a range of optimistic comments surfaced over the weekend and earlier today. US biotechs can be found among the biggest pre-market movers following announcement of a multi-billion dollar rights deal.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
S&P 500 (US500) index managed to halt downward move ahead of the support zone ranging above the 2800 pts handle. With today’s rebound the chance of maintaining current 2800-2960 pts trading range increases. In case no news concerning trade war surface in the days to come, a move towards the upper limit of the range may be on the cards now. Source: xStation5
Amgen to buy worldwide rights for Otezla drug from Celgene
Amgen (AMGN.US), Celgene (CELG.US) and Bristol-Myers Squibb (BMY.US), the US biotech companies, are making moves in the pre-market trading. Amgen announced that it will buy worldwide rights to Otezla drug from Celgene. The deal is valued at $13.4 billion and is a part of divestiture plan pursued by Celgene (CELG.US) and Bristol-Myers Squibb (BMY.US). The latter two companies announced a merger at the beginning of the year and try to get regulatory green light by selling off some assets. Completion of the Otezla sale will only go through in case the approval for the merger is granted. Sales of Otezla drug reached $1.76 billion in 4 quarters ended on 30 June 2019. Celgene and Bristol are trading higher while Amgen moved lower on the news.
Amgen surged at the beginning of the month and broke above the 200-session moving average as well as the downward sloping trendline. An upward move was halted by the zone marked with highs from September and December 2018. The stock is poised to start today’s trading lower and $195 handle may be the level to watch. Source: xStation5
Tesla to hasten price increases in China
According to the Reuters report, Tesla (TSLA.US) will raise prices for its cars on Friday, somewhat quicker than previously planned. The price increase is partially driven by weakening of yuan that harms the company's sales as Tesla is importing cars it sells in China. Moreover, the very same report hints that this may not be the end of trade war related price increases. The US electric vehicle manufacturer is also said to consider another price hike in December in case tariffs on US cars are indeed imposed. However, one should keep in mind that this news was provided to Reuters by unnamed insider and has not been confirmed by the company yet.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
